EUROPEAN JOURNAL OF CANCER
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
available at www.sciencedirect.com
journal homepage: www.ejconline.com
Review
High-throughput techniques in breast cancer:
A clinical perspective
Enrique Espinosa*, Andrés Redondo, Juan Ángel Fresno Vara, Pilar Zamora,
Enrique Casado, Paloma Cejas, Manuel González Barón
‘‘Service of Medical Oncology’’, Hospital La Paz – Universidad Autónoma, Paseo de la Castellana, 261, 28046 Madrid, Spain
A R T I C L E I N F O
A B S T R A C T
Article history:
High-throughput technologies such as DNA-microarrays, RT-PCR and proteomics can
Received 10 June 2005
improve the prognostic and predictive information acquired from classical parameters.
Accepted 22 November 2005
Unlike information gathered by classical methods, high-throughput technologies can accu-
Available online 23 January 2006
rately inform clinicians on patient response to adjuvant therapy or those who will resist the
effect of that therapy. Studies performed in breast cancer with high-throughput techniques
Keywords:
have focused on tumour biology, prognosis, prediction of response to a few agents and,
Breast cancer
more recently, early diagnosis. However, further refinement is needed before these tech-
Clinical trials
niques become part of clinical routine. In the meantime, they will be used in clinical inves-
DNA microarrays
tigation, particularly in the areas of hormonal therapy and adjuvant chemotherapy, where
PCR
modest improvements in the capacity of prediction can benefit many women. Close coop-
Treatment outcome
eration among clinicians, pathologists and basic investigators is essential to take high-
Prognosis
throughput techniques to daily practice. New diagnostic tools will be complex but they will
Proteomics
provide valuable patient information.
Review
1.
Ó 2005 Elsevier Ltd. All rights reserved.
Introduction
The outcome of patients with breast cancer has improved in
the last 20 years due to early diagnosis and the widespread
use of adjuvant therapies. This outcome can be predicted
with the help of clinical and pathological parameters, the
so-called prognostic factors. However, currently available
prognostic factors are far from accurate and they must be improved. New high-throughput technologies are now being
used in an attempt to enhance our prognostic and predictive
capacities, which could help in determining the best adjuvant
treatment for every patient.
In this review, we shall deal with the limitations of classical prognostic factors, the main features of high-throughput
techniques and what they should offer before being incorporated to daily clinical practice. Our objective is to offer a global
perspective that is useful for the physician and basic
investigator.
2.
Prognostic factors and adjuvant treatment
of breast cancer
2.1.
Early-stage disease
Women with localized tumours usually undergo a conservative surgical procedure, followed by radiotherapy and
adjuvant systemic treatment. The latter consists of chemotherapy, hormonal therapy or both, and is given with the
* Corresponding author: Tel.: +34 917 277 000; fax: +34 917 277 118.
E-mail addresses: eespinosa00@terra.es (E. Espinosa), mgonzalezb.hulp@salud.madrid.org (M.G. Barón).
0959-8049/$ - see front matter Ó 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2005.11.021
EUROPEAN JOURNAL OF CANCER
aim of decreasing the chance of relapse and death. The likelihood that a patient will benefit from adjuvant therapy depends on several classical prognostic factors: number of
affected lymph nodes, size of the tumour, grade of differentiation and expression of hormonal receptors and ERBB2.1–6
Table 1 shows disease-free survival values according to the
lymph node status and the size of the tumour, the two main
prognostic factors.
Nowadays, most patients receive some kind of adjuvant
chemotherapy. Although chemotherapy improves the longterm outcome of women with breast cancer, it induces alopecia, nausea, vomiting and fatigue, among other side-effects.
On the other hand, patients whose tumours express hormonal receptors are treated with hormones for at least five
years. Hormones may produce hot flushes, loss of libido, vaginal discharge, muscular or joint pain and accelerated loss of
bone density. Noteworthy, toxicity derived from chemotherapy or hormonal therapy appears in all women, not only in
those obtaining a benefit.
The main limitation of both chemotherapy and hormonal
therapy is that the absolute gain in survival is small in many
instances, even with very active schemes7 (Fig. 1). This means
that most patients receiving systemic therapy will not benefit
599
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
Table 1 – Disease-free survival for breast cancer
depending on the size of the tumour and the lymph-node
status1–5
Size (cm)
Disease-free survival (%)
Negative lymph nodes
Up to 2
2–5
Over 5
80–90
70
60
Positive lymph nodes
Up to 2
2–5
Over 5
63–50
50–35
35–21
No. of positive lymph nodes
Disease-free survival (%)
1–3
4–9
10 and over
55
35
15
For any given size of the primary tumour, the presence of axillary
lymph nodes decreases the likelihood of disease-free survival.
Lymph node status is the most powerful clinical prognostic factor.
Regardless of the size of the tumour, the number of affected lymph
nodes is directly related to the outcome. Patients with four or more
lymph nodes are considered to have locally-advanced disease.
Shared Decision Making
Shared Decision Making
Name: _________________________________________ (Breast Cancer)
Age: 55 General Health: Excellent
Name: _________________________________________ (Breast Cancer)
Age: 40 General Health: Excellent
Estrogen Receptor Status: Positive Histologic Grade: 2
Tumor Size: 1.1 - 2.0 cm Nodes Involved: 0
Chemotherapy Regimen: Anthra, >4 cycles, >2 agents
Estrogen Receptor Status: Positive Histologic Grade: 3
Tumor Size: 2.1 - 3.0 cm Nodes Involved: 1 - 3
Chemotherapy Regimen: CA * 4 + T * 4
Decision: No Additional Therapy
Decision: No Additional Therapy
31 out of 100 women are alive and without cancer in 10 years.
68 out of 100 women relapse.
1 out of 100 women die of other causes.
72 out of 100 women are alive and without cancer in 10 years.
25 out of 100 women relapse.
3 out of 100 women die of other causes.
Decision: Hormonal Therapy
Decision: Hormonal Therapy
28 out of 100 women are alive and without cancer because of therapy.
12 out of 100 women are alive and without cancer because of therapy.
Decision: Chemotherapy
Decision: Chemotherapy
22 out of 100 women are alive and without cancer because of therapy.
7 out of 100 women are alive and without cancer because of therapy.
Decision: Combined Therapy
Decision: Combined Therapy
44 out of 100 women are alive and without cancer because of therapy.
16 out of 100 women are alive and without cancer because of therapy.
A
B
Fig. 1 – Estimation of disease-free survival and gain with adjuvant therapy in two patients by using AdjuvantTM Software7
(with permission). (A) A 55-year-old patient with a good prognosis. Adjuvant therapy consists of fluorouracil–doxorubicin–
cyclophosphamide followed by anastrozole. Anastrozole alone provides a 12% reduction in the rate of relapse, whereas
chemotherapy alone contributes with 7%. If both therapies are combined, the relapse rate decreases by 16%: this is less than
the sum of those separately (the effect is not additive), indicating that, if the patient is going to receive hormones – benefit
12% –, chemotherapy will add only an absolute benefit of 4%. (B) A 40-year-old woman with a poor prognosis tumour.
Adjuvant therapy consists of doxorubicin–cyclophosphamide + paclitaxel followed by anastrozole. The absolute gain (white
area) is greater for the second patient whatever the combination of adjuvant therapy, but even so only one out of six patients
will benefit from chemotherapy if they are also treated with hormones. The first situation is far more common than the
second, so the absolute gain with adjuvant therapy is moderate for the average patient.
600
EUROPEAN JOURNAL OF CANCER
from it, either because they will be cured just with local treatments or because they will relapse anyway. Currently available prognostic factors are not good enough to predict
outcome accurately, hence the difficulty in selecting patients
who will benefit most from adjuvant systemic therapy.
2.2.
Locally-advanced disease
Women with tumours greater than 5 cm or with P4 or palpable axillary lymph nodes have locally-advanced disease. They
may undergo either a mastectomy or preoperative chemotherapy followed, if the response is good, by conservative
surgery and radiotherapy. Preoperative (neoadjuvant) chemotherapy has two main objectives: to allow a conservative
surgical procedure and to improve survival. Of note, survival
improvement is greater in patients achieving a pathological
complete response, approximately 10–20% of those with
locally-advanced disease.8–10
Obviously, tumours with primary resistance to chemotherapy will not shrink with neoadjuvant therapy. Drug resistance
may depend on many factors, but we have limited information
in this regard.11 So far, there is no way to identify who will
have a complete response, nor is it possible to predict lack of
response to chemotherapy, a situation where delaying surgical
therapy might be deleterious. It follows that, in locallyadvanced disease, prognostic factors, i.e., those related to survival, are less important than predictive factors, i.e., those
indicating the likelihood to respond to a given therapy.
2.3.
Disseminated disease
Metastatic breast cancer is an incurable disease. Although few
women survive for five years or longer, most of them have a
life expectancy of two to three years from the diagnosis of
the metastasis.12,13 Many patients experience some kind of
benefit from first or second line therapies (either hormones
or chemotherapy), but the chances of responding decrease
thereafter with every new line of treatment. As in the cases
of early-stage and locally-advanced disease, however, we cannot identify who will respond to a particular treatment (with
the obvious exception of lack of response to hormones in cases
with negative hormonal receptors). Something similar applies
to trastuzumab, a monoclonal antibody directed against
ERBB2: positive FISH or immunohistochemistry staining is
required to begin therapy with the antibody, but responses
appear only in one third of these selected patients.14,15
As a summary, clinical and pathological factors do not
accurately indicate which patients will require adjuvant therapy or which tumours will be resistant to anticancer drugs.
New factors are obviously needed to optimize cancer therapy
and high-throughput techniques could be of help in this
regard.
3.
A brief explanation of high-throughput
techniques
3.1.
Genomics
DNA microarrays and quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) have been used to per-
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
form gene profiling in breast cancer. Profiles from different
samples can be compared to each other: for instance, normal versus tumoural tissues; or samples coming from patients with poor versus good outcome; or those who
responded versus those who did not respond to a given therapy. A microarray is a solid support containing thousands of
different gene fragments called probes. Probes consist of
complementary DNA or oligonucleotides. The device is put
in contact with a mixture of complementary RNA or complementary DNA derived from the study sample. If the sample
contains a gene that is present in the microarray, hybridization will take place. The signal present in each probe is automatically detected, quantified and integrated with
specialized hardware and software, which yields the gene
expression profile for that sample. Data can be used to improve either our understanding of oncogenesis (discovering
key genes or characterization of pathways) or the management of patients, as we shall discuss later. Arrays for
gene expression profiling can now accommodate the whole
genome.16–18
On the other hand, qRT-PCR capitalizes on the fact that
there is a quantitative relationship between the amount of
starting target sample and the amount of PCR product at
any given PCR cycle number. The concept of ‘real-time’ PCR
consists of the detection of PCR products as they accumulate.19,20 Current qRT-PCR systems are based on a set of primers and fluorogenic probes, which accounts for the high
specificity of the technique. The amount of fluorescence produced from these fluorogenic probes is measured at each
amplification cycle, providing a look at the ‘‘real-time’’
changes in the amplification product as the PCR process
develops. Identification of the PCR cycle when the exponential growth phase is first detectable provides extremely accurate quantitation of gene expression in the starting samples.
This cycle number is called the threshold cycle and is inversely proportional to the starting amount of target genetic
material.
From a clinical point of view, qRT-PCR has some advantages over DNA-microarrays: it requires smaller quantities of
valuable tumour tissue and provides accurate, easily reproducible and quantitative results with less manipulation of
the sample.21,22 Unlike microarrays, many pathologists are
familiar with this technique. Moreover, recent reports suggest
the possibility of using paraffin-embedded tumour tissue with
qRT-PCR.23,24 Quantitative-PCR devices analyse a limited
number of genes simultaneously, so that they are not ideal
for a first approach, but once screening has been performed
with microarrays, they have the advantage of being easier
to manufacture and standardize. For these reasons, if a profile
containing a limited number of genes would be accepted for
use in the clinic, qRT-PCR or a similar technique would be a
practical choice.22
Other techniques have also been used to study breast
tumours. Comparative genomic hybridization (CGH) is a
method to detect chromosomal copy number by comparing
hybridization intensity of a tumour and a normal control
DNA sample.25 Array-based CGH makes it possible to scan
the whole genome for copy number alterations with high resolution by hybridizing genomic representative DNA to arrayed
oligonucleotides, BAC (bacterial artificial chromosome) or
EUROPEAN JOURNAL OF CANCER
cDNA clones that correspond to multiple regions of the
genome.26–28
Finally, single nucleotide polymorphism (SNP) arrays have
also been developed.29 SNPs are single-letter variations in
DNA base sequence and represent the most common source
of genetic variation in the human genome (about one in 300
bases). SNP analysis is useful for a variety of applications,
such as copy number30 or linkage analysis to identify disease-related genes.31,32
3.2.
Proteomics
Protein-microarrays rely on the same principle as their DNA
counterparts, thus allowing the simultaneous assessment of
hundreds to thousands of proteins. The results can offer
information about the functional state of the encoded proteins, as well as information about protein to protein interactions.33 For this reason, protein-microarrays are becoming
more relevant in this field. A new type of protein array, reverse-phase protein array, has been successfully used with
small amounts of tissues.34
Tissue microarrays are means of combining tens to hundreds of specimens from paraffin-embedded tissue and, less
commonly, from frozen tissue. A tissue microarray slide can
be processed like an ordinary tissue section, and used for histochemical, immunohistochemical staining or in situ hybridization.35 Whereas gene arrays can examine thousands of
genes per sample, tissue microarrays generally study only a
single gene product in tens to hundreds of samples. Thus,
the technologies are in some respects opposed, although
highly complementary. The system may allow the fast validation of multiple biomarkers, a process that would take weeks
if performed by classical immunohistochemistry.36 A common criticism is that assessment of an entire tissue section
is more accurate than a small spot of tissue on an array, but
some groups have shown excellent concordance between tissue microarray spots and whole sections in immunohistochemistry.37,38
The detection of the whole set of proteins can be accomplished with mass spectrometry.39 A mass spectrometer
separates proteins (and other analytes) according to their
mass-to-charge (m/z) ratio. Mass spectrometers generally couple three devices: an ionization device, a mass analyzer, and a
detector. The molecule is ionized by one of several techniques,
and the ion is propelled into a mass analyzer by an electric
field that resolves each ion according to its m/z ratio. The
detector passes the information to the computer for analysis.
The most common ionization techniques used in biology are
matrix-assisted laser desorption ionization (MALDI), its derivative surface enhanced laser desorption/ionization (SELDI)
and electrospray ionization (ESI). Mass spectrometry technology is fast and requires small amounts of the protein sample.
Samples can consist of any fresh or frozen tissue samples,
including blood or tumour specimens. Promising evaluations
of diagnostic proteomic profiles have been reported from serum samples in patients with tumours of the ovary and prostate.40,41 SELDI-TOF MS ProteinChip technology has recently
been used for the diagnosis of breast carcinoma.42 In spite of
that, experts agree that mass spectrometry needs further validation before it is adopted in clinical practice.34
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
3.3.
601
Limitations
The requirement of frozen samples to process the genetic
material with high-throughput techniques limits their widespread use. This outlines the importance of tumour banks,
although some investigators have successfully used paraffin-embedded tumour tissue to circumvent the problem.43
Another important limitation is the overwhelming volume
of data generated in these studies. Specialized software has
been developed, but there is still much room for improvement and an experienced statistician must analyse the data.
Finally, high-throughput techniques are very expensive compared to those traditionally used for the pathological workup. These difficulties explain why new technologies will
not gain access to daily clinical practice until they prove their
superiority with regard to classical factors. This will require
close cooperation among clinicians, basic investigators and
statisticians.
4.
Studies in breast cancer
High-throughput techniques have been used in normal breast
tissue and tumours with different clinical or pathological features. Studies most interesting for clinicians relate to prognosis and response prediction. The main results with clinical
implications can be summarized as follows.
4.1.
Breast cancer biology
1. The expression profiles of distinct pathological stages of
breast cancer, i.e., early versus advanced disease have
remarkable similarities.44–46 In contrast, benign tissue
shows quite a different expression of genes. This suggests
that the capacity to metastasize appears soon in the natural history of breast cancer, so that the gene expression
profile of early-stage disease reflects the metastatic potential of the lesion. The hypothesis has been confirmed in
further studies that demonstrate a correlation between
the profile of the primary tumour and the prognosis.46,47
From a clinical point of view, it is well known that even
small primaries may produce metastases.
2. Some sets of genes correlate with the presence of oestrogen receptors.48,49 This includes not only genes related to
the hormonal pathway, but also genes encoding proteins
that synergise with oestrogens. It follows that the hormonal status does not only define the adjuvant treatment,
but also divides tumours into genetically different categories. It has long been recognized that tumours with expression of hormonal receptors produce less relapses and have
a more indolent course.
3. Microarrays can identify at least five types of tumour subclasses in ductal carcinomas: normal breast-like, basallike, ERBB2 and luminal types A and B.50 The basal-like
and ERBB2 subclasses are associated with shortest survival
times, as opposite to the luminal A type. Tumours in carriers of BRCA-1 mutations usually correspond to the basallike subclass.51 This is one of the first proposals for a
genetic classification of breast cancer. Our current classification relies on pathological description, where most
tumours are ductal, followed by the lobular type, but this
602
EUROPEAN JOURNAL OF CANCER
division does not provide much information about the
clinical outcome. A genetic taxonomy supports the observation that the clinical evolution of breast cancer is extremely heterogeneous. So far, clinicians can only speculate
that there are different diseases with a similar pathological appearance. A new classification also opens the possibility to explore the pathogenesis of the disease and to
develop targeted therapies in the future. Specific profiling
of BRCA tumours has also been performed,52,53 confirming
that BRCA tumours are genetically different from other
varieties of breast cancer.
4.2.
Prognosis and adjuvant treatment
A 70-gene expression profile predicts outcome in premenopausal women with early-stage breast cancer even better
than the lymph node status.47 We have reproduced these results with qRT-PCR.54 Besides, a 21-gene profile predicts the
likelihood of distant recurrence in tamoxifen-treated patients
with node-negative breast cancer.24 This profile identifies up
to 50% of patients whose prognosis with hormonal therapy
is so good that chemotherapy could be avoided.24,55 Finally,
a 76-gene signature does so in women with node-negative
disease and no adjuvant therapy.56 For the first time, physicians may use genetic factors that rival node status in the
capacity to predict outcome, but unlike the situation of the
lymph nodes, genetic tests may also provide information to
customise adjuvant treatment, as we shall discuss later.
Some protein profiling studies have also been performed
with tissue microarrays. A French group identified a set of
21 proteins which correlated with metastasis-free survival.57
A British group used a large panel of markers to delineate five
groups with distinct patterns of expression.58 In both cases,
correlation was found with the five subclasses previously
determined by DNA-microarray technology.
4.3.
Response prediction and advanced disease
Some studies have found gene expression profiles predicting
response to taxanes59–61 or tamoxifen.23,62,63 A study of cDNA
microarrays in poor-prognosis tumours treated with anthracycline-based adjuvant chemotherapy found a 23-gene set
that was associated with different survival.64 On the other
hand, single-nucleotide polymorphisms can contribute to
individual drug response.65,66 This is an area of paramount
importance. Current therapeutic strategies are planned with
no information about the susceptibility of the tumour to anticancer drugs in a given patient, so that this patient has to face
side-effects with no guarantee of success. Particularly in advanced disease, time is everything and if one line of treatment fails, the prognosis worsens dramatically. We must
also consider the huge economic cost of ineffective drugs.
Unfortunately, results in this area of investigation are still
far from the clinic and a lot more studies will be required in
the near future.
4.4.
Early diagnosis
Proteomic techniques have been used more recently to focus
on the analysis of blood samples to develop a rapid diagnostic
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
test,67,68 early detection of relapse in nipple aspiration,69,70
the characterization of ductal carcinoma in situ71 and the response to neoadjuvant chemotherapy.72 Data from these
studies are however, too preliminary.
5.
Criteria to be met by molecular profiling
technologies before introduction to the clinic
The aforementioned results could lead the reader to think
that high-throughput techniques can already become part
of routine pathological workup, particularly in early-stage
disease, but some requirements still need to be fulfilled.
Firstly, most centres do not have these techniques available
and their staff lacks appropriate training to use them. Only
when this is accomplished will results become available fast
enough for clinicians and their patients. Most oncologist
agree that effective adjuvant chemotherapy should begin
within one month after surgery, a concept based on some
classical studies.73,74 Also, neoadjuvant chemotherapy is
usually begun a few days after the initial biopsy. Even in
the absence of definitive data about the ideal timing of chemotherapy, women prefer to know as soon as possible
whether they will need it, as well as what kind of chemotherapy. If a high-throughput technique was to be used in
the clinic, qRT-PCR would have advantages over microarrays
in terms of simplicity and reproducibility, although one can
imagine a future ready-to-use DNA chip that is also simple.
As we said before, procedures should be refined so that paraffin-embedded or even cytology material could be used instead of frozen samples. The need for reproducible and
easily available methods has been previously emphasized.75
Secondly, different platforms and profiles have been validated. To date, we have no data to favour one over the other.
As none of them has 100% accuracy, they will need further
refinement and, after that, universal profiles should be
agreed. Ideally, these new markers should not only inform
about prognosis but also about the probability of response
to different therapies (predictive value). In the same way that
pathologists routinely report on size, lymph nodes, grade of
differentiation, hormonal status and ERBB2 expression, future platforms and profiles should provide standard information, so that results are comparable among studies and
institutions.
Finally, methodological problems may create pitfalls in the
interpretation of results. Previous studies included limited
numbers of patients, which is not enough to change clinical
standards based on solid trials that have recruited thousands
of patients in the past. A recent analysis demonstrated that
molecular signatures strongly depend on the selection of patients in the training sets, so that validation studies should be
performed with all candidate profiles.76 Besides cohort selection and validation of results, other methodological issues
that should be carefully addressed are the statistical analysis
and the reporting of raw data.77
In spite of their associated problems, these new technologies are here to stay and will certainly be used to improve our
knowledge of prognosis. An open question is what kind of
studies should be performed to reliably validate new molecular markers that complement classical prognostic and predictive markers.
EUROPEAN JOURNAL OF CANCER
6.
Design of clinical trials using gene profiles
Molecular markers hold great promise for refining our ability
to establish early diagnosis and prognosis, and to predict response to therapy. The fact that techniques and profiles
should be improved does not mean that we cannot begin
using them in clinical trials. High-throughput techniques will
have to undergo a thorough process of validation in the same
way as any other new diagnostic or therapeutic tool. So, what
kind of gene profile trials could have the greatest clinical
impact?
6.1.
Early diagnosis and follow-up
Proteomics has shown promising results in the early detection of disease, but this is the least developed area. Women
at high risk of having breast cancer could be screened by
radiological methods as well as proteomic technologies from
blood samples to assess the predictive power of the new technique. Patient sample profiling could even help in selecting
patients for chemoprevention trials. In the short or medium
term, similar trials could also be performed in women with
aggressive tumours, to detect early relapses. However, important concerns have been raised about the validity of serum
proteomic pattern analysis by mass spectrometry for early
cancer diagnosis.78
6.2.
Trials with hormonal therapy
Approximately 60% of patients with early-stage disease have
tumours with positive hormonal receptors and they all receive hormones, even when only a fraction will benefit
(Fig. 1). In the case of advanced disease, first-line hormonal
therapy obtains an objective response or stabilization in
approximately 60% of the patients. Although less serious than
those of chemotherapy, these drugs also produce side-effects.
Economical savings could be another reason to encourage
studies in this regard. As a consequence, the identification
of patients who do not benefit from hormones should become
a priority in the next decade.
Recent reports have identified gene profiles that can predict either response to tamoxifen in metastatic breast cancer62
or resistance in the adjuvant setting.24 Similar studies should
be performed with aromatase inhibitors. These trials will take
time, particularly in the adjuvant setting, as patients treated
with hormones usually have low-risk disease, which means
low risk of relapse and death.
6.3.
Trials with chemotherapy in node-negative disease
The EORTC (European Organisation for the Research and
Treatment of Cancer) will shortly begin a trial to validate a
70-gene profile in women with node-negative breast cancer.
Patients’ risk will be defined with either the St. Gallen prognostic index (based on classical factors) or the gene profile:
women having a low risk of relapse as defined with either
method will not receive adjuvant chemotherapy, whereas
the remaining patients will receive chemotherapy (±hormones). The purpose of the trial is to compare the outcome
of patients in both low-risk groups. Twenty percent of women
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
603
with negative nodes have low risk of relapse according to St.
Gallen’s index, as compared to 40% with the gene profile. If
disease-free survival is comparable, 20% of women could be
spared adjuvant chemotherapy in the future by using the
molecular method. A 20% looks modest considering the
sophistication of the information provided by high-throughput techniques, but it could include thousands of women
across Europe and the United States every year. To demonstrate the hypothesis, the trial will recruit 5000 patients79.
On the other hand, in the United States, the Intergroup will
initiate another clinical trial using the 21-gene profile, as part
of the Program for Assessment of Clinical Cancer Tests
(PACCT). Women with intermediate-risk recurrence score will
be randomized to receive adjuvant hormonal therapy with or
without chemotherapy. This study will also include about
5000 patients. It follows that for the moment, trials using
gene profiles will not include fewer patients than similar trials validating classical prognostic factors.
Even if these gene profiles are validated in the aforementioned trials, further improvements will be needed. In the
EORTC trial for instance, 60% of women with an unfavourable
gene signature would receive adjuvant chemotherapy based
on this profile, whereas the proportion with greatest benefit
is lower in node-negative disease (Fig. 1a). On the other hand,
there are clinical differences in the behaviour of tumours
depending on the hormonal status and histology, but we do
not yet understand the genetic background that explains such
differences. For instance, negative-receptor tumours usually
behave more aggressively than positive tumours, and lobular
carcinomas have a particular pattern of relapse. When new
and supposedly better profiles are discovered in the future,
they should also undergo clinical evaluation under similar
conditions. Data bases and samples from big multi-institutional trials could be used to validate these improved profiles.
6.4.
Trials with chemotherapy in high-risk disease
The next question could be if we can spare useless chemotherapy in patients defined as having high risk of relapse
according to classical prognostic factors. This is more difficult. Fig. 1 shows that the risk of relapse and the benefit obtained with adjuvant chemotherapy grow in parallel, so a
trial with the EORTC design for low-risk women would be
unacceptable in the high-risk situation. For high-risk patients,
checking chemo-resistance would be of more interest. Women with tumours that are very unlikely to respond to standard chemotherapy could be offered entering clinical trials
with new agents or even no chemotherapy at all. However,
this kind of trial is now difficult to implement for two main
reasons: first, we have few data regarding gene profiles that
predict resistance to chemotherapy; and second, trials of
adjuvant therapy require many patients and take a long time
(it is not possible to get conclusions until a significant proportion of the patients have relapsed).
For this purpose, the neoadjuvant setting, therapy before
surgery, offers the possibility to assess the clinical response
in a more simple way. Biopsies can be obtained at diagnosis
for the molecular study, whereas the final response to chemotherapy is known after surgery. For example, the SPORE trial
will try to identify genes that exhibit differences between
604
EUROPEAN JOURNAL OF CANCER
responding and non-responding tumours before treatment
with neoadjuvant paclitaxel (www.cancer.gov).
However, target response groups are slightly different in
neoadjuvant and adjuvant settings. In the first case, it is
important to identify patients who will have a pathological response, because they experience a survival advantage. In the
second case, identifying chemo-resistance would be more
appropriate, and this could include a different set of genes.
A profile predicting lack of response to neoadjuvant chemotherapy should then be checked in the adjuvant setting.
Fig. 2 illustrates this issue.
6.5.
Trials in metastatic disease
Many genetic factors are involved in response to anti-tumour drugs.11 Physicians treating patients with advanced
breast cancer do not know in advance whether a given tumour will respond to chemotherapy or hormones. Unlike
the neoadjuvant and adjuvant settings, single agent therapy
plays an important role in advanced disease, so that trials
could assess resistance to individual drugs rather than to
combination regimens. In first or second lines, knowing
about drug sensitivity would allow to select the most active
options for a particular patient. In third or subsequent lines,
where the chances of response are usually low, this information could be used to give advice and share therapeutic decisions with the patient.
6.6.
Other issues
New investigations are also considering host factors. The genetic background on which the tumour grows influences its
Pathological
complete resp.
Partial response
Stable or
progression
Response to
Neoadjuvant
chemotherapy
Most useful for
neoadjuvant
chemotherapy
Chemosensitive
Potentially useful for
adjuvant chemotherapy
Chemoresistant
Fig. 2 – Areas of interest for neoadjuvant and adjuvant
chemotherapy. In the case of neoadjuvant chemotherapy,
the ideal gene profile should identify patients who obtain a
pathological complete response (grey area), because these
women achieve longer survival. This profile cannot be used
in the adjuvant setting, as it would exclude too many
people: a useful adjuvant profile should identify only
patients with resistant disease (black area) i.e., women who
are very unlikely to benefit from adjuvant chemotherapy.
The difference in concept must be considered when
designing clinical trials.
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
ability to metastasize. For instance, differences of the target
stroma to support angiogenic conversion in response to tumour-secreted growth factors may influence in this regard.
Whenever laser microdissection is not used, samples contain
cells from both the normal stroma and the tumour, so that
high-throughput techniques are evaluating also host factors.
In the same way, subtle variations in the ability to mount
an immune response could partially explain the patient’s
outcome.80
Drug metabolism, hence drug activity or toxicity, depends
on drug-metabolizing enzymes, which could be assessed
either by RT-PCR or microarrays.81 The activity of some of
these enzymes is modulated by polymorphisms present in
some individuals,66,82 so that routine detection of some
polymorphisms can be of interest.
Finally, epigenetic changes affecting gene expression can
be related to prognosis, as demonstrated by recent investigations.83,84 This issue could also be considered in the future to
assess prognosis.
7.
Future directions
High-throughput techniques are not likely to replace current
pathological workup, but will rather be complementary.
These new techniques should be used by pathologists, so they
will have to incorporate them into their training and practice.
But the most successful and efficient research about clinically
useful molecular markers will require effective interdisciplinary communication and collaboration integrating the knowledge of clinicians, biochemists, and statisticians.
Consensus on platforms and profiles will be certainly
needed in the future, so that we can use this information in
the same way we work with standard pathological reports.
As this technology is evolving very fast at the moment, it will
take time to reach such a consensus. In every profile described so far, a lot of genes being apparently independent
might be in an overlapping network. Before an ideal profile
is accepted, functional pathways must be fully characterized.
Making raw data available on the internet may help other scientists in validating profiles, so that profile accuracy is improved as data on more and more patients are incorporated.
Obviously, only profiles supported by good clinical trials will
have a chance of being widely accepted. Fig. 3 shows a representation of what could be an ‘‘ideal’’ profile for the future.
Such a profile could be tailored according to the centre protocols or the clinical setting (neoadjuvant, adjuvant, advanced
disease).
Gene profiling will not only be used to get prognostic and
predictive data, but also to identify potential therapeutic targets. This step is required to synthesize new drugs that broaden our armamentarium against breast cancer and other
tumours. It follows that a number of different profiles will
be used in the future depending on the objectives pursued,
either clinical or investigational, and obtained with DNAmicroarrays, RT-PCR or tissue-microarrays.
Gene expression and genotyping do not provide all the
information about tumoural biology: protein detection could
also play a role. Standard operating procedures must be
established for sample handling and processing before proteomics is broadly adopted. At this moment, it is not possible
EUROPEAN JOURNAL OF CANCER
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
605
Fig. 3 – Representation of an ‘‘ideal’’ gene-profile providing both prognostic and predictive information. Clinical data from
new trials can be incorporated into a computer-based model to improve its accuracy, adding or deleting genes from the
original profile. The clinician could ask the model for specific information. The profile could be tailored to provide specific
predictive information for the therapeutic protocols in a given centre.
to know whether this technique will substitute for gene profiling or if they will be complementary.
With all this in mind, we can predict that genetic tools in
the future will include a mixture of tumour and host features.
Considering the heterogeneity of breast cancer and the number of factors to be included, general prognosis, resistance to
different drugs, these tools will certainly be complex, but they
will provide valuable information to improve the outcome of
our patients.
Conflict of interest statement
The authors declare that they do not have any conflict of
interest.
R E F E R E N C E S
1. Rosen PR, Groshen S, Saigo PE, et al. A long-term follow-up
study of survival in stage I (T1N0M0) and stage II (T1N1M0)
breast carcinoma. J Clin Oncol 1989;7:355–66.
2. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and
survival following radical mastectomy, analysis of 716
consecutive patients. Cancer 1978;41:1170–8.
3. Kuru B, Camlibel M, Ali Gulcelik M, et al. Prognostic factors
affecting survival and disease-free survival in lymph
node-negative breast carcinomas. J Surg Oncol 2003;83:
167–72.
4. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph
node status, and survival in 24,740 breast cancer cases. Cancer
1989;63:181–7.
5. Weiss RB, Woolf SH, Demakos E, et al. Natural history of more
than 20 years of node-positive primary breast carcinoma
treated with cyclophosphamide, methotrexate, and
fluorouracil-based adjuvant chemotherapy: a study by the
Cancer and Leukemia Group B. J Clin Oncol 2003;21:1825–35.
6. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and
protein in breast cancer 2003: biomarker and target of
therapy. Oncologist 2003;8:307–25.
7. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based
validation of the prognostic model ADJUVANT! for early
breast cancer. J Clin Oncol 2005;23:2716–25.
8. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative
chemotherapy on the outcome of women with operable
breast cancer. J Clin Oncol 1998;16:2672–85.
9. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of
breast cancer patients with complete pathologic primary
tumor and axillary lymph node response to doxorubicin-based
neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–9.
10. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative
chemotherapy in primary operable breast cancer: results
from the European Organization for Research and Treatment
of Cancer trial 10902. J Clin Oncol 2001;19:4224–37.
11. Longley DB, Johnston PG. Molecular mechanisms of drug
resistance. J Pathol 2005;205:275–92.
12. Vogel CL, Azevedo S, Hilsenbeck S, et al. Survival after first
recurrence of breast cancer. The Miami experience. Cancer
1992;70:129–35.
13. Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting
survival from first recurrence in patients with metastatic
breast cancer: analysis of 439 patients. Breast Cancer Res Treat
1999;56:67–78.
14. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer
with analysis of efficacy by HER2 immunophenotype and
gene amplification. J Clin Oncol 2001;19:2587–95.
606
EUROPEAN JOURNAL OF CANCER
15. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of
trastuzumab as a single agent in first-line treatment of
HER2-overexpressing metastatic breast cancer. J Clin Oncol
2002;20:719–26.
16. Kallioniemi OP. Biochip technologies in cancer research. Ann
Med 2001;33:142–7.
17. Lakhani SR, Ashworth A. Microarray and histopathological
analysis of tumours: the future and the past? Nat Rev Cancer
2001;1:151–7.
18. Cooper CS. Applications of microarray technology in breast
cancer research. Breast Cancer Res 2001;3:158–75.
19. Mocellin S, Rossi CR, Pilati P, et al. Quantitative real-time PCR:
a powerful ally in cancer research. Trends Mol Med
2003;9:189–95.
20. Bieche I, Lerebours F, Tozlu S, et al. Molecular profiling
of inflammatory breast cancer: identification of a
poor-prognosis gene expression signature. Clin Cancer Res
2004;10:6789–95.
21. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of
pulmonary adenocarcinoma by expression profiling of eight
genes as determined by quantitative real-time reverse
transcriptase polymerase chain reaction. J Clin Oncol
2004;22:811–9.
22. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of
survival in diffuse large-B-cell lymphoma based on the
expression of six genes. N Engl J Med 2004;350:1828–37.
23. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio
predicts clinical outcome in breast cancer patients treated
with tamoxifen. Cancer Cell 2004;5:607–16.
24. Paik S, Shak S, Tang G, et al. A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.
25. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative
genomic hybridization for molecular cytogenetic analysis of
solid tumors. Science 1992;258:818–21.
26. Maguire P, Holmberg K, Kost-Alimova M, et al. CGH analysis
of familial non-BRCA1/BRCA2 breast tumors and mutation
screening of a candidate locus on chromosome 17q11.2-12. Int
J Mol Med 2005;16:135–41.
27. Mao X, Hamoudi RA, Zhao P, et al. Genetic losses in breast
cancer: toward an integrated molecular cytogenetic map.
Cancer Genet Cytogenet 2005;160:141–51.
28. Nessling M, Richter K, Schwaenen C, et al. Candidate genes in
breast cancer revealed by microarray-based comparative
genomic hybridization of archived tissue. Cancer Res
2005;65:439–47.
29. Lucito R, Healy J, Alexander J, et al. Representational
oligonucleotide microarray analysis: a high-resolution
method to detect genome copy number variation. Genome Res
2003;13:2291–305.
30. Zhao X, Li C, Paez JG, et al. An integrated view of copy
number and allelic alterations in the cancer genome using
single nucleotide polymorphism arrays. Cancer Res
2004;64:3060–71.
31. Benusiglio PR, Lesueur F, Luccarini C, et al. Common ERBB2
polymorphisms and risk of breast cancer in a white British
population: a case-control study. Breast Cancer Res
2005;7:R204–9.
32. Hoyal CR, Kammerer S, Roth RB, et al. Genetic
polymorphisms in DPF3 associated with risk of breast
cancer and lymph node metastases. J Carcinog 2005;4:13.
33. MacBeath G. Protein microarrays and proteomics. Nat Genet
2002;32(Suppl. 5):26–32.
34. Wulfkuhle J, Espina V, Liotta L, et al. Genomic and proteomic
technologies for individualisation and improvement of
cancer treatment. Eur J Cancer 2004;40:2623–32.
35. Braunschweig T, Chung JY, Hewitt SM. Perspectives in tissue
microarrays. Comb Chem High Throughput Screen 2004;7:575–85.
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
36. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a
new technology for amplification of tissue resources. Cancer J
2001;7:24–31.
37. Camp RL, Charette LA, Rimm DL. Validation of tissue
microarray technology in breast carcinoma. Lab Invest
2000;80:1943–99.
38. Hendriks Y, Franken P, Dierssen JW, et al. Conventional and
tissue microarray immunohistochemical expression analysis
of mismatch repair in hereditary colorectal tumors. Am J
Pathol 2003;162:469–77.
39. Aebersold R, Mann M. Mass spectrometry-based proteomics.
Nature 2003;422:198–207.
40. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic
patterns in serum to identify ovarian cancer. Lancet
2002;359:572–7.
41. Petricoin 3rd EF, Ornstein DK, Paweletz CP, et al. Serum
proteomic patterns for detection of prostate cancer. J Natl
Cancer Inst 2002;94:1576–8.
42. Li J, Orlandi R, White CN, et al. Independent validation of
candidate breast cancer serum biomarkers identified by mass
spectrometry. Clin Chem 2005;51:2229–35.
43. Cronin M, Pho M, Dutta D, et al. Measurement of gene
expression in archival paraffin-embedded tissues:
development and performance of a 92-gene reverse
transcriptase-polymerase chain reaction assay. Am J Pathol
2004;164:35–42.
44. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of
human breast cancer progression. Proc Natl Acad Sci USA
2003;100:5974–9.
45. Lacroix M, Toillon RA, Leclercq G. Stable ‘portrait’ of breast
tumors during progression: data from biology, pathology and
genetics. Endocr Relat Cancer 2004;11:497–522.
46. Weigelt B, Glas AM, Wessels LF, et al. Gene expression profiles
of primary breast tumors maintained in distant metastases.
Proc Natl Acad Sci USA 2003;100:15901–5.
47. van de Vijver MJ, He YD, van’t Veer LJ, et al. A geneexpression signature as a predictor of survival in breast
cancer. N Engl J Med 2002;347:1999–2009.
48. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor
status in breast cancer is associated with remarkably
distinct gene expression patterns. Cancer Res 2001;61:
5979–84.
49. West M, Blanchette C, Dressman H, et al. Predicting the
clinical status of human breast cancer by using gene
expression profiles. Proc Natl Acad Sci USA 2001;98:11462–7.
50. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression
patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci USA
2001;98:10869–74.
51. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA 2003;100:8418–23.
52. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression
profiles in hereditary breast cancer. N Engl J Med
2001;344:539–48.
53. Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct
genomic profiles in hereditary breast tumors identified by
array-based comparative genomic hybridization. Cancer Res
2005;65:7612–21.
54. Espinosa E, Vara JA, Redondo A, et al. Breast cancer prognosis
determined by gene expression profiling: a quantitative
reverse transcriptase polymerase chain reaction study. J Clin
Oncol 2005;23:7278–85.
55. Fisher B, Jeong JH, Bryant J, et al. Treatment of
lymph-node-negative, oestrogen-receptor-positive breast
cancer: long-term findings from National Surgical Adjuvant
Breast and Bowel Project randomised clinical trials. Lancet
2004;364:858–68.
EUROPEAN JOURNAL OF CANCER
56. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to
predict distant metastasis of lymph-node-negative primary
breast cancer. Lancet 2005;365:671–9.
57. Jacquemier J, Ginestier C, Rougemont J, et al. Protein
expression profiling identifies subclasses of breast cancer and
predicts prognosis. Cancer Res 2005;65:767–79.
58. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput
protein expression analysis using tissue microarray
technology of a large well-characterised series identifies
biologically distinct classes of breast cancer confirming
recent cDNA expression analyses. Int J Cancer
2005;116:340–50.
59. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression
profiling for the prediction of therapeutic response to
docetaxel in patients with breast cancer. Lancet
2003;362:362–9.
60. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles
predict complete pathologic response to neoadjuvant paclitaxel
and fluorouracil, doxorubicin, and cyclophosphamide
chemotherapy in breast cancer. J Clin Oncol 2004;22:2284–93.
61. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of
docetaxel response in human breast cancer by gene
expression profiling. J Clin Oncol 2005;23:422–31.
62. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular
classification of tamoxifen-resistant breast carcinomas by
gene expression profiling. J Clin Oncol 2005;23:732–40.
63. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen
resistance by a conformational arrest of the estrogen receptor
alpha after PKA activation in breast cancer. Cancer Cell
2004;5:597–605.
64. Bertucci F, Nasser V, Granjeaud S, et al. Gene expression
profiles of poor-prognosis primary breast cancer correlate
with survival. Hum Mol Genet 2002;11:863–72.
65. McLeod HL, Yu J. Cancer pharmacogenomics: SNPs, chips, and
the individual patient. Cancer Invest 2003;21:630–40.
66. Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in
glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and
survival after chemotherapy for invasive breast carcinoma.
Cancer 2005;103:52–8.
67. Vlahou A, Laronga C, Wilson L, et al. A novel approach
toward development of a rapid blood test for breast cancer.
Clin Breast Cancer 2003;4:203–9.
68. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and
bioinformatics approaches for identification of serum
biomarkers to detect breast cancer. Clin Chem
2002;48:1296–304.
69. Paweletz CP, Trock B, Pennanen M, et al. Proteomic patterns
of nipple aspirate fluids obtained by SELDI-TOF: potential for
new biomarkers to aid in the diagnosis of breast cancer. Dis
Markers 2001;17:301–7.
70. Sauter ER, Zhu W, Fan XJ, et al. Proteomic analysis of nipple
aspirate fluid to detect biologic markers of breast cancer. Br J
Cancer 2002;86:1440–3.
4 2 ( 2 0 0 6 ) 5 9 8 –6 0 7
607
71. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of
human breast ductal carcinoma in situ. Cancer Res
2002;62:6740–9.
72. Pusztai L, Gregory BW, Baggerly KA, et al. Pharmacoproteomic
analysis of prechemotherapy and postchemotherapy plasma
samples from patients receiving neoadjuvant or adjuvant
chemotherapy for breast carcinoma. Cancer 2004;100:
1814–22.
73. Pronzato P, Campora E, Amoroso D, et al. Impact of
administration-related factors on outcome of adjuvant
chemotherapy for primary breast cancer. Am J Clin Oncol
1989;12:481–5.
74. Colleoni M, Bonetti M, Coates AS, et al. Early start of
adjuvant chemotherapy may improve treatment outcome
for premenopausal breast cancer patients with tumors
not expressing estrogen receptors. The International
Breast Cancer Study Group. J Clin Oncol 2000;18:
584–90.
75. Van’t Veer LJ, Paik S, Hayes DF. Gene expression profiling of
breast cancer: a new tumor marker. J Clin Oncol
2005;23:1631–5.
76. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome
with microarrays: a multiple random validation strategy.
Lancet 2005;365:488–92.
77. Ahmed A, Brenton J. Microarrays and breast cancer clinical
studies: forgetting what we have not yet learnt. Breast Cancer
Res 2005;7:96–9.
78. Diamandis EP, van der Merwe DE. Plasma protein profiling by
mass spectrometry for cancer diagnosis: opportunities and
limitations. Clin Cancer Res 2005;11:963–5.
79. Tuma RS. A big trial for a new technology: TransBIG Project
takes microarrays into clinical trials. J Natl Cancer Inst
2004;96:648–9.
80. Hunter KW. Host genetics and tumour metastasis. Br J Cancer
2004;90:752–5.
81. Michael M, Doherty MM. Tumoral drug metabolism: overview
and its implications for cancer therapy. J Clin Oncol
2005;23:205–29.
82. Alba E, Martin M, Ramos M, et al. Multicenter randomized
trial comparing sequential with concomitant administration
of doxorubicin and docetaxel as first-line treatment of
metastatic breast cancer: a Spanish Breast Cancer Research
Group (GEICAM-9903) phase III study. J Clin Oncol
2004;22:2587–93.
83. Harbeck N, Bohlmann J, Ross J, et al. Multicenter study
validates PITX2 DNA methylation for risk prediction in
tamoxifen-treated node-negative breast cancer using
paraffin-embedded tumor tissue. Annual Meeting of the
American Society of Clinical Oncology, Orlando; 2005. p. 5s.
84. Umetani N, Mori T, Koyanagi K, et al. Aberrant
hypermethylation of ID4 gene promoter region increases
risk of lymph node metastasis in T1 breast cancer. Oncogene
2005;24:4721–7.